CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CUV

CUV - CLINUVEL PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.05
Index: ASX300 | ALL-ORDS

Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$9.18

27 Aug
2026

-1.340

OPEN

$10.50

-12.74%

HIGH

$10.85

481,909

LOW

$8.57

TARGET
$12.25 33.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CUV: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 67.8 67.4 xxx
DPS (cps) xxx 5.0 6.0 xxx
EPS Growth xxx - 6.1% - 0.6% xxx
DPS Growth xxx 0.0% 20.0% xxx
PE Ratio xxx N/A 12.6 xxx
Dividend Yield xxx N/A 0.7% xxx
Div Pay Ratio(%) xxx 7.4% 8.9% xxx

Dividend yield today if purchased 3 years ago: 0.25%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.59

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 5.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx67.8
DPS All xxxxxxxxxxxxxxx5.0
Sales/Revenue xxxxxxxxxxxxxxx94.0 M
Book Value Per Share xxxxxxxxxxxxxxx541.1
Net Operating Cash Flow xxxxxxxxxxxxxxx36.9 M
Net Profit Margin xxxxxxxxxxxxxxx36.07 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx13.21 %
Return on Invested Capital xxxxxxxxxxxxxxx13.16 %
Return on Assets xxxxxxxxxxxxxxx11.93 %
Return on Equity xxxxxxxxxxxxxxx13.21 %
Return on Total Capital xxxxxxxxxxxxxxx15.74 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx32.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx252 M
Price To Book Value xxxxxxxxxxxxxxx1.90

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx1.6 M
Capex % of Sales xxxxxxxxxxxxxxx1.70 %
Cost of Goods Sold xxxxxxxxxxxxxxx16 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx38 M
Research & Development xxxxxxxxxxxxxxx18 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxxxxxx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

27/02/2026

1

Speculative Buy

$13.00

41.61%

Clinuvel Pharmaceuticals' 1H26 result was softer than Morgans expected, with product revenue up 4% y/y and EBITDA falling - 23%, as operating cost growth materially outpaced revenue and FX moved to a loss.

The balance sheet is strong but continued to reflect underutilisation of capital, commentary states. Expenses rose 22% y/y reflecting ongoing clinical investment, with margin compression likely to persist into 2H26.

The outlook remains tied to clinical catalysts, notably CUV105 Phase 3 vitiligo topline data in 2H26 and NEURACTHEL filings in 2026, the analyst remarks.

Target price slips to $13 from $14. Speculative Buy retained.

FORECAST
Morgans forecasts a full year FY27 dividend of 7.00 cents and EPS of 73.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Moelis

05/03/2026

1

Buy

$23.29

153.70%

First-half revenue for Clinuvel Pharmaceuticals rose 4% on the prior year to $36.9m. Moelis observes stronger EU sales offset weaker US revenue affected by government shutdown-related payment processing delays.

Earnings (EBITDA) fell -45% to $9.8m, while profit declined -26% to $10.4m, though the result was broadly in line with the broker’s expectations.

EU revenue increased 45% following an expansion in the recommended treatment regime for erythropoietic protoporphyria (EPP), explain the analysts.

Progress in vitiligo trials remains on track with key data expected in H2 2026.

FY26-28 earnings forecasts are broadly unchanged, with Moelis noting FX headwinds in the US are offset by stronger EU sales and lower costs.

Buy rating and $23.29 target price are unchanged.

FORECAST
Moelis forecasts a full year FY27 dividend of 5.60 cents and EPS of 88.70 cents.
Access Extra Coverage Research History >

CUV STOCK CHART

FNArena News on CUV

1
FNArena Corporate Results Monitor – 28-08-2026

Aug 28 2026 - Australia
2
Australian Broker Call *Extra* Edition – Mar 10, 2026

Mar 10 2026 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Mar 05, 2026

Mar 05 2026 - Daily Market Reports
4
FNArena Corporate Results Monitor – 27-02-2026

Feb 27 2026 - Australia
5
Weekly Ratings, Targets, Forecast Changes – 14-11-25

Nov 17 2025 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
2
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
3
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
4
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
5
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
6
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
7
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
8
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
9
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
10
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps